Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy in adults.
Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and 40% of its mass accounted for by oxygen. Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.
Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients above 2 years of age 4)Prophylaxis of migraine in children 12 years of age and older and adults.
Topiramate is also used off-label as an adjunct therapy for weight management and for mood disorders.
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Matrix Institute on Addictions, Costa Mesa, California, United States
John A. Burns School of Medicine, Honolulu, Hawaii, United States
University of Missouri - Kansas City, Kansas City, Missouri, United States
UVA CARE, Charlottesville, Virginia, United States
UVA CARE Richmond, Richmond, Virginia, United States
Swedish Headache Clinic, Seattle, Washington, United States
Monarch Medical Research - Child and Adolescent Neurology, Norfolk, Virginia, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.